Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

Exclusion Criteria

• •Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days (for small molecules) whichever is longer; or longer if required by local regulations.
• •Previous treatment, including the use of any investigational agents, for the treatment of HCV infection.
• •Women of child bearing potential.
• •Subjects with IL-28b genotype "CT or TT".
• •ALT γ-GT, and AST must be below 5 x the upper limit of normal (ULN).
• •Serum bilirubin must not exceed ULN.
• •The PT (INR) must be within normal limits.
• •If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to randomization, to rule out any laboratory error.
• •Use of drugs that inhibit or induce CYP3A4.